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Objectives: To analyze the frequency of S-globin haplotypes and alpha-thalassemia, and
their inﬂuence on clinical manifestations and the hematological proﬁle of children with
sickle cell anemia.
Method: The frequency of S-globin haplotypes and alpha-thalassemia and any association
with  clinical and laboratorial manifestations were determined in 117 sickle cell anemia
children aged 3–71 months. The conﬁrmation of hemoglobin SS and determination of
the  haplotypes were achieved by polymerase chain reaction-restriction fragment length
polymorphism, and alpha-thalassemia genotyping was by multiplex polymerase chain
reaction (single-tube multiplex-polymerase chain reaction).
Results: The genotype distribution of haplotypes was 43 (36.7%) Central African
Republic/Benin, 41 (35.0%) Central African Republic/Central African Republic, 20 (17.0%)
Rare/atypical, and 13 (11.1%) Benin/Benin. The frequency of the 3.7 deletion was 1.71%
as  homozygous (−3.7/−3.7) and 11.9% as heterozygous (−3.7/). The only signiﬁ-
cant association in respect to haplotypes was related to the mean corpuscular volume.
The  presence of alpha-thalassemia was signiﬁcantly associated to decreases in mean
corpuscular volume, mean corpuscular hemoglobin and reticulocyte count and to an
increase in the red blood cell count. There were no signiﬁcant associations of S-globin
haplotypes and alpha-thalassemia with clinical manifestations.
Conclusions: In the study population, the frequency of alpha-thalassemia was similar
to  published data in Brazil with the Central African Republic haplotype being the most
common, followed by the Benin haplotype. S-globin haplotypes and interaction between
alpha-thalassemia and sickle cell anemia did not inﬂuence fetal hemoglobin concentrations
or  the number of clinical manifestations.
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ickle cell anemia (Hb SS) is characterized by homozygosity
or hemoglobin S (Hb S), consequent to a point mutation in
he 6th codon of the -globin gene on chromosome 11.1,2 It is
he most prevalent hereditary hematologic disease in Brazil
ith elevated morbidity and mortality. It is estimated that
500 children are born with Hb SS annually, one in every 1000
ive births, whereas the frequency of heterozygotes in the gen-
ral population is 2–8%.3,4 The clinical state of these patients
s exceptionally variable, which may be inﬂuenced by differ-
nt factors, such as the haplotypes of the S-globin gene, the
resence of alpha-thalassemia, and the fetal hemoglobin level
Hb F).1,2
Haplotypes of the S-globin gene are determined by speciﬁc
olymorphism patterns in the  gene complex. They origi-
ate from different regions of Africa, from which they receive
heir denominations: CAR or Bantu (Central African Republic),
enin (West Africa), Senegal (West Africa), Cameroon (West
frica) and Saudi-Indian (Asia, India and the Arabian Penin-
ula). Polymorphism sets not recognized by these classical
atterns are referred to as atypical (ATP) and occur at a rate
f 5–10%.5,6 In Brazil, due to the forced migration of African
escendants, CAR and Benin (BEN) haplotypes are the most
ommon.5,7–11
Alpha-thalassemia is the result of deﬁcient synthesis of
 globin chains in hemoglobin (Hb). The  chain genes are
ocated on chromosome 16, and normal individuals have two
 genes on each chromosome with this genotype being rep-
esented as /.12 The 3.7 deletion, which causes the
ost common form of alpha-thalassemia in Brazil,13 is the
esult of an unequal cross-over exhibiting a loss of a 3.7 kb
NA fragment.14 Recent Brazilian studies show different
revalences for the 3.7 genotype according to the geograph-
cal ancestry of the individuals studied: 4.5% in European
nd 21.5% in African descendants,15 data similar to those
btained in populations of African descents by Sonati et al.16
razilian studies analyzing alpha-thalassemia in individuals
ith Hb SS present prevalences of 3.7 heterozygous indi-
iduals of from 17.6 to 28.2%, according to the geographic
egion.9–11,13,17
The interaction between Hb SS and alpha-thalassemia is
ssociated with an inhibition of Hb S polymerization2,18,19
hich decreases hemolytic episodes2,18 entailing reductions
n mean corpuscular volume (MCV) and mean corpus-
ular hemoglobin (MCH) compared to Hb SS individuals
ithout alpha-thalassemia.20 An improvement in the
atients’ clinical state is observed with reductions in
ickle cell crises.18,21 The presence of alpha-thalassemia
s also signiﬁcantly associated with a reduction in
hite blood cell (WBC)15 and reticulocyte2,17 counts, and
ncreased levels of Hb A2.17,22–25 Although there is no
eﬁned relationship, increased levels of Hb F are also
eported.2,24
The objective of this study was to assess the prevalence of
S-globin haplotypes and alpha-thalassemia in a group of chil-
ren with Hb SS and their inﬂuence on hematological proﬁle
nd clinical manifestations. 1 4;3  6(5):334–339 335
Methods
This was a cross-sectional study with convenience sampling
involving 117 of 122 under 6-year-old children with Hb SS, no
matter the severity of the disease, attended at the Pediatric
Hematology Outpatient Clinic of the Escola Paulista de Medi-
cina, Universidade Federal de São Paulo. The samples were
collected from September 2007 to December 2009; the age var-
ied from 3 to 71 months (median age of 35.5 months) and 62
(52.99%) of the children were male. The study was approval
by the Research Ethics Committee of the Escola Paulista de
Medicina, Universidade Federal de São Paulo.
Exclusion  criteria
Patients who had received red blood cell transfusions in the 3
months prior to sample collection and those receiving hydrox-
yurea were excluded from the study.
Clinical  and  laboratorial  variables
Clinical and laboratorial variables were obtained from the
patient’s medical records. The following laboratorial criteria
were analyzed: Hb level, hematocrit (Ht), red blood cell (RBC),
WBC, MCV, MCH, reticulocyte, and platelet counts, and Hb F
levels.
The clinical variables were analyzed considering whether
the patients had <3 or ≥3 types of manifestations per
year including vaso-occlusive crisis (VOC), acute chest syn-
drome/pneumonia (ACS/PNM), infections (acute osteomyelitis
and urinary tract infection) and episodes of acute splenic
sequestration.
Molecular  analysis
DNA was extracted from WBCs in peripheral blood using
phenol–chloroform extraction and ethanol precipitation.26
The Hb S mutation was conﬁrmed by polymerase chain
reaction-restriction fragment length polymorphism (PCR-
RFLP).27 Single-tube multiplex-PCR was used for alpha-
thalassemia genotyping using primers standardized by Chong
et al.28 Determination of the haplotypes of the s gene com-
plex was performed by PCR-RFLP analysis using primers as
proposed by Sutton et al.29 All tests were conducted using a
thermal cycler from Veriti Applied Biosystems® (Foster City,
CA, USA).
Statistical  analysis
Non-parametric tests were used for statistical analysis taking
into account the variability and distribution of the study vari-
ables. Kruskal–Wallis with the Dunn test was used to compare
more  than two samples, and the Mann–Whitney test for two
independent samples. Signiﬁcance was set for alpha errors of
5% (p-value <0.05); statistically analysis was performed using
the InStat-2 (GraphPad®, San Diego, CA, USA) and SigmaStat
3.11 software (Systat® Software, Chicago, IL, USA).
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Results
The frequencies of haplotypes were 57.26% for CAR, 33.33%
for BEN, 8.12% for ATP, 0.85% for SAUDI and 0.43% for Sene-
gal. The genotype distribution was CAR/BEN in 43 (36.75%)
patients, CAR/CAR in 41 (35.04%), Rare/ATP in 20 (17.09%) and
BEN/BEN in 13 (11.11%). In the 20 Rare/ATP patients, the follow-
ing combinations were identiﬁed: BEN/ATP in eight patients
(6.84%), CAR/ATP in seven (5.98%), ATP/ATP in two (1.71%),
and one individual (0.85%) with the SEN/CAR, SAUDI/CAR, and
SAUDI/BEN haplotypes.
Even though the CAR/CAR group presented lower lev-
els of Hb F than the other groups, no statistical difference
was observed. MCV  was different between the CAR/BEN
and BEN/BEN haplotypes (p-value = 0.01) (Table 1). A com-
parison between different haplotypes showed no difference
concerning the number of clinical manifestations presented
(p-value = 0.22) (data not shown).
In relation to the occurrence of alpha-thalassemia, two
patients (1.71%) were homozygous for the 3.7 deletion and 14
(11.97%) heterozygous, totaling 13.68% of alpha-thalassemia
individuals (16/117). The alpha-thalassemia group (homozy-
gotes and heterozygotes) presented signiﬁcant reductions in
MCV, MCH and reticulocyte counts, and had a signiﬁcant
increase in the RBC count compared to the group without
the deletion. Although Hb F levels in the alpha-thalassemia
group were higher in relation to the group without alpha-
thalassemia (18.3%; range: 4.2–31.1 vs. 17.8%; range: 1.8–51.3,
respectively) no signiﬁcance was detected (p-value = 0.84)
(Table 2). Regarding the number of clinical manifestations,
there was no signiﬁcant difference between the groups (p-
value = 0.66).
Table 3 shows the frequency of alpha-thalassemia in rela-
tion to the S-globin haplotypes. Signiﬁcant differences were
observed in MCV  values between individuals with and with-
out alpha-thalassemia in the CAR/CAR and CAR/BEN groups
(p-value = 0.002 and 0.017, respectively) (Table 4).
Discussion
S-globin gene haplotypes are being studied in Brazil and
in other countries with the objective of determining their
frequency in different regions and their inﬂuence on the
clinical manifestations of Hb SS, since this is not yet well
characterized.2 Alpha-thalassemia has also been considered
an important modifying factor of clinical severity in Hb SS
as it reduces hemolytic episodes and alters the hematological
proﬁle of patients.18
In patients with Hb SS, the elevated concentration of Hb
F protects against vaso-occlusive events, consequently reduc-
ing clinical manifestations. Steinberg30 reported that Hb F is
the most powerful disease modiﬁer and Powars1 stated that,
in being related to low Hb F levels, the CAR haplotype is associ-
ated with more  severe clinical manifestations, while SEN and
SAUDI haplotypes present high Hb F levels with milder clinical
manifestations, and the BEN haplotype presents intermediate
Hb F levels and clinical course.
rev bras hematol hemoter. 2 0 1 4;3  6(5):334–339 337
Table 2 – Hematological data expressed as medians (range), according to presence of 3.7 thalassemia in 117 sickle cell
anemia children.
3.7 thalassemia p = (<0,05)a
Absence Presence
n Median (range) n Median (range)
Hemoglobin (g/dL) 98 8.5 (6.5–10.5) 16 8.5 (7.1–9.5) 0.637
Hematocrit (%) 98 22.0 (14.7–30.7) 11 22.6 (20.1–28.7) 0.471
RBC (×1012/L) 72 2.6 (1.8–4.4) 10 3.0 (2.5–4.0) 0.040
MCV (fL) 90 83.5 (59.0–95.0) 12 74.4 (62.9–83.7) 0.0001
MCH (pg) 89 28.8 (22.1–35.2) 12 26.3 (20.0–28.7) 0.002
WBC (×109/L) 99 18.1 (5.7–32.9) 12 17.2 (7.0–21.8) 0.608
Platelets (×109/L) 98 390 (125–932) 12 396 (285–591) 0.795
Reticulocytes (%) 64 9.8 (1.5–22.0) 8 4.1 (0.7–13.2) 0.021
Hemoglobin F (%) 77 17.8 (1.8–51.3) 11 18.3 (4.2–31.1) 0.874
3.7 thalassemia: heterozygous and homozygous; RBC: red blood cells; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin;
WBC: white blood cells.
a Mann–Whitney.
Table 3 – Frequency of alpha-thalassemia according to
S-globin haplotypes in 117 children with sickle cell
anemia.
Haplotypes / 3.7 thalassemia
n (%) n (%)
CAR/BEN 37 (31.62) 6 (5.13)
CAR/CAR 35 (29.91) 6 (5.13)
BEN/BEN 11 (9.4) 2 (1.71)
CAR/ATP 6 (5.13) 1 (0.85)
BEN/ATP 8 (6.84) 0
ATP/ATP 2 (1.71) 0
SAUDI/CAR 1 (0.85) 0
SAUDI/BEN 1 (0.85) 0
SEN/CAR 0 1 (0.85)
Total 101 (86.32) 16 (13.68)
3.7 thalassemia: homozygous and heterozygous; CAR: Central
c
a
B
f
t
C
iopathology of Hb SS, hence the importance of assessingAfrican Republic; BEN: Benin; SEN: Senegal; SAUDI: Asia, India and
the Arabian Peninsula; ATP: atypical.
In the current study, the CAR haplotype was the most
ommon haplotype encountered, followed by BEN; these data
re similar to other studies conducted in the southeast of
razil.5,7–11 Despite the fact that there was no signiﬁcant dif-
erence in Hb F levels among haplotypes, these values follow
he pattern described in the literature, that is, lower values in
AR/CAR and CAR/BEN genotypes, followed by BEN/BEN.7,10
Table 4 – Mean corpuscular volume (MCV) presented as median
to the presence of 3.7 thalassemia.
Haplotypes 3.7 thala
Absence 
n Median (range) 
CAR/CAR 30 85.3 (68.5–95.0) 
CAR/BEN 32 81.4 (59.0–89.2) 
3.7 thalassemia: homozygous and heterozygous; CAR: Central African Re
a Mann–Whitney.No signiﬁcant difference was observed in the number of
clinical manifestations between the haplotype types, proba-
bly due to the fact that the studied population presented a
mean age of 37 months, when Hb F levels are still elevated
in Hb SS individuals,31 and many  clinical manifestations are
not apparent at this age. Another possible factor might be
the miscegenation of the Brazilian population and consequent
elevated number of individuals with heterozygous haplotypes.
A study conducted by Silva Filho et al.11 with a similar age
group, encountered similar results.
The Rare/ATP group consists of different haplotype com-
binations, mostly involving CAR haplotype heterozygotes
(11/25 = 44%) rather than heterozygotes and homozygotes with
the ATP haplotype. According to Zago et al., 6 ATP haplotypes
can be considered a variation of the Bantu haplotype, and thus
we can suppose that they might be related to greater severity
of the disease. Although the rare haplotypes (SEN and SAUDI)
are associated with a milder clinical course, they did not
inﬂuence the results obtained as they were identiﬁed in only
three patients, conﬁrming their low prevalence in the study
region.7
Some hematological parameters are related to the severity
of the disease and are directly implicated in the phys-their association with haplotypes and alpha-thalassemia.
In the comparison between the different haplotype groups,
the CAR/CAR group presented signiﬁcantly lower Hb levels,
 (range) in CAR/CAR and CAR/BEN haplotypes according
ssemia p-valuea
Presence
n Median (range)
6 77.4 (59.6–79.6) 0.002
3 71.1 (67.2–75.1) 0.017
public; BEN: Benin.
oter.
r
1
1
1
1
1
1
1
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followed by the CAR/BEN. These data are similar to results by
Silva Filho et al.11 and de Neonato et al.24
Low MCV  and MCH  values are associated with a reduc-
tion in the synthesis of  chains and related to the effect that
alpha-thalassemia exerts on the polymerization of Hb S and
on the deformity of sickled cells, making them less dense.20
Other than this, there is evidence that microcytosis, per se,
exert beneﬁcial effects on vaso-occlusive complications in
Hb SS.2,21
The frequency of alpha-thalassemia in the study popu-
lation was similar to that found in other Brazilian studies
performed on patients with Hb SS.9,10,17
Hb values did not differ between the groups with or with-
out alpha-thalassemia, similar to the results reported by Silva
Filho et al.11 and Stevens et al.23 Signiﬁcant reductions in
MCV and MCH  levels and reticulocyte counts, and a signiﬁcant
increase in the RBC count in 3.7 deletion patients conﬁrms
data in the literature.2,17,22 There was no statistically signiﬁ-
cant difference in the WBC  count between the groups, contrary
to other publications that reported a reduction in the WBC
count in individuals with alpha-thalassemia.17,22
Hb F levels did not show any signiﬁcant difference between
the two groups, similar to results obtained by Silva Filho
et al.,11 Belisário et al.17 and Mouélé et al.,22 in studies con-
ducted with similar age groups.
The current study did not observed any inﬂuence of alpha-
thalassemia on clinical manifestations, different to other
studies where the presence of alpha-thalassemia preserved
splenic function, leading to persistence of splenomegaly in
patients with homozygous 3.7 deletion.31 The fact that Hb F
is still elevated in the study group might also justify the lack of
inﬂuence of the deletion in alpha-thalassemia on the clinical
manifestations of these patients.
One factor that might be considered as a bias in this study
is that data collection of clinical events was from the patients’
medical records, which could be considered deﬁcient. How-
ever the patients were followed-up in the institution, not
only in the outpatient clinic but also in the emergency
ward and during hospitalization, which reduces or discards
bias caused by dependence on the memory  of the patient’s
family.
Conclusions
The frequency of alpha-thalassemia in this study was similar
to previous studies in Brazil, with the CAR haplotype being the
most common, followed by the BEN haplotype. The S-globin
gene haplotypes and the presence of alpha-thalassemia did
not inﬂuence the levels of Hb F or the number of clinical man-
ifestations presented. We believe that a prospective follow-up
of these patients will provide more  knowledge on the inﬂu-
ence of alpha-thalassemia and the S-globin gene haplotypes
on clinical manifestations in Hb SS.Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
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